Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — J.P. Morgan Healthcare Conference 2026
19 slides from Regeneron Pharmaceuticals's conference presentation, Jan 12, 2026
Slide 1: J.P. Morgan Healthcare Conference
J a n u a r y 1 2 , 2 0 2 6 J.P. Morgan Healthcare Conference This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially.
Slide 2: Presenters
2 J.P. Morgan Healthcare Conference Dr. Leonard Schleifer, MD, PhD Board Co-Chair, Co-Founder, President, & Chief Executive Officer Dr. George Yancopoulos, MD, PhD Board Co-Chair, Co-Founder, President, & Chief Scientific Officer
Slide 3: Note regarding forward-looking statements and non-GAAP financial measures
3 Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual ev
Slide 4: Delivering Breakthrough Medicines
4 Note: Definitions for all acronyms and abbreviations in this presentation can be found on slide 19. Leveraging the power of science to bring transformative medicines to patients... over and over again 14 internally-discovered therapies have been approved, poised to deliver many more… Delivering Br
Slide 5: Portfolio of leading brands across diverse therapeutic areas
prescribed biologic for Type 2 #1 inflammatory diseases $2,629 $3,205 $3,619 $1,036 $1,140 $1,238 Q1 2025 Q2 2025 Q3 2025 5 Portfolio of leading brands across diverse therapeutic areas Delivering growth through leadership in key therapeutic categories * Based on preliminary, unaudited results. Fourt
Slide 6: Deploying capital to maximize long-term value creation
6 Deploying capital to maximize long-term value creation Disciplined capital allocation approach laying the foundation for Regeneron’s next wave of innovation * Reflects estimated Non-GAAP R&D expense, which excludes SBC. GAAP R&D expense for 2026 is estimated to be ~$6.5 billion. Formal financial g
Slide 7: Driving shareholder value with internal innovation
7 Driving shareholder value with internal innovation while continuing our disciplined and opportunistic approach to business development Over-reliance on business development (BD) to build pipelines poses challenges to delivering long-term shareholder value Cash flow allocation: Level of investment
Slide 8: Regeneron pipeline targets large market opportunities across key therapeutic categories
Regeneron pipeline targets large market opportunities across key therapeutic categories Ophthalmology Oncology Hematology Cardiovascular & Metabolic Diseases Neurology & Rare Diseases $15B+ $55B+ $60B+ $15B+ $50B+ $10B+ T H E R A P E U T I C A R E A S Global market opportunity ~$200B annually by 203
Slide 9: Pipeline across therapeutic areas
9 Cemdisiran (C5 siRNA) ± Pozelimab (C5 Ab)* Paroxysmal nocturnal hemoglobinuria REGN7508CAT (FXI) Post-TKR VTE, Cancer VTE, PICC-associated thrombosis, SPAF, PAD REGN9933A2 (FXI) PICC-associated thrombosis, SPAF, PAD This slide contains investigational drug candidates that have not been approved by
Slide 10: Sustaining I&I leadership and unlocking new growth opportunities
10 Sustaining I&I leadership and unlocking new growth opportunities Leveraging learnings from Dupixent and disease biology to advance next-gen approaches to treat inflammatory diseases ‘Lifecycle’ opportunities • Longer Dupixent* dosing intervals • Novel long-acting IL-4Rα † antibody • Long-acting,
Slide 11: Late-stage opportunities spanning multiple therapeutic areas
Late-stage opportunities spanning multiple therapeutic areas Key programs positioned to deliver over the next few years *Hansoh Pharmaceuticals retains development and commercialization rights to olatorepatide in China. 11 This slide contains investigational drug candidates that have not been approv
Slide 12: Fianlimab + cemiplimab melanoma data vs. standards of care
Pembrolizumab (anti-PD-1) KEYNOTE-006 n=277 (Q3W) Nivolumab (anti-PD-1) RELATIVITY-047 n=359 Ipilimumab (anti-CTLA4) + nivolumab CHECKMATE-067 n=314 Relatlimab (anti-LAG-3) + nivolumab CHECKMATE-067 n=314 Fianlimab + cemiplimab Pooled POC Cohorts n=98 mPFS 4.1 4.6 11.7 10.1 24 (KM estimate) mOS (mon
Slide 13: LYNOZYFIC Vision
LYNOZYFIC Vision 1L: Improve patient options with simpler and less intense regimens while maintaining efficacy and increasing physician flexibility TE: Enhanced efficacy with ASCT or as ASCT alternative TIE: Simpler, less intense and more convenient option Maintenance: Simpler, less intense and more
Slide 14: Tailored C5 therapeutic approach: siRNA ± antibody
14 Tailored C5 therapeutic approach: siRNA ± antibody provides flexibility to address multiple complement-mediated diseases siRNA (cemdisiran) lowers C5 target burden while antibody (pozelimab) blocks circulating C5, enabling near-complete C5 inhibition * Evaluate Pharma † There are no randomized, h
Slide 15: Regeneron's broad Factor XI clinical program
25% 28% 32% 48% R7508 + Aspirin R9933 + Aspirin Aspirin Rivaroxaban (Xarelto®) + Aspirin Trial initiating in 1H 2026, initial data expected in 2029+ Phase 2 enrolling, data expected in 2027 Phase 3 trials to initiate in 2026 Trial to initiate in 2026, data expected in 2028+ Two trials enrolling, dat
Slide 16: Transforming patient care for obesity and related conditions
16 Transforming patient care for obesity and related conditions Three major opportunities for Regeneron in the rapidly growing obesity therapeutic area This slide contains investigational drug candidates that have not been approved by any regulatory authority. 1 GIP/GLP-1 Receptor Agonist monotherap
Slide 17: Q&A
Q&A This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Dr. George Yancopoulos, MD, PhD Board Co-Chair, Co-Founder, President, and Chief Scientific Officer Dr. Leonard Schleifer, MD, PhD Board Co-Chair, Co-Founder
Slide 18: 2026 Key Milestones
18 2026 Key Milestones Hematology • R7508/R9933: Initiate additional Phase 3 trials in anticoagulation (1H26) • Cemdisiran ± Pozelimab: report results from Phase 3 trial in PNH (4Q26 / 1Q27) Oncology Solid Oncology • Fianlimab + cemiplimab: Report results in 1L metastatic melanoma from Ph3 trial (1H
Slide 19: Abbreviations and definitions
19 Abbreviations and definitions Abbreviation Definition 1L First line AAV Adeno-associated virus ALA Amyloid light-chain amyloidosis ALS Amyotrophic lateral sclerosis AI Artificial Intelligence AD Atopic Dermatitis AATR Transthyretin amyloidosis BCC Basal cell carcinoma BCMA B-cell maturation antig
Regeneron Pharmaceuticals — J.P. Morgan Healthcare Conference 2026 on 6ix